UNSPSC 51171832: Benzquinamide

This classification denotes an antiemetic agent with the molecular formula C22H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0475EA27Q3, chemically known as 3-diethylcarbamoyl-2,3,4,6,7,11b-hexahydro-9,10-dimethoxy-1h-benzo(a)chinolizin-2-yl acetat but generally known as benzquinamide, which bears US NIH Compound Identifier 2342. Benzquinamide most often comes in base and hydrochloride forms.

UNSPSC 51171832 Benzquinamide, a Commodity code, represents pharmaceutical products acquired by state and local governments primarily through specimen collection and drug testing programs, pharmacy benefit initiatives, and multistate cooperative purchasing arrangements for generic and over-the-counter medications. The code sees activity across correctional supervision departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Recent solicitations show state and local buyers procuring benzquinamide and related pharmaceuticals within broader drug screening panels, direct-to-manufacturer prescription programs, and generic pharmaceutical supply contracts that serve corrections facilities, employee health plans, and distributed state and local healthcare networks.

Collin County Community Supervision and Corrections Department (Texas) issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services with a response deadline of July 23, 2026, seeking approximately 25,031 annual tests including five-panel and six-panel screening with LC/MS/MS or GC/MS confirmation under a two-year contract valued at $600,000 with three optional one-year renewal periods. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs and vendor capabilities for pharmacy benefit initiatives, and the Minnesota Department of Administration, acting through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), posted RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, establishing multiple awards across participating state and local government facilities in Minnesota and Oregon effective July 1, 2026. Recent activity centers in Texas and Minnesota, with procurement spanning correctional drug testing, state pharmaceutical benefit programs, and cooperative purchasing vehicles serving multiple jurisdictions.